VEGF — Drug Target

All drugs that target VEGF — marketed and clinical-stage. Includes 11 drug classes acting on this target.

Drug classes

anti-VEGF agent · Antiangiogenic agent · VEGF decoy receptor · anti-VEGF inhibitor · chemotherapy regimen · VEGF aptamer and microtubule inhibitor · Anti-angiogenic agent · Antiangiogenic agent and Immunomodulator · monoclonal antibody · Angiogenesis inhibitor and platinum-based chemotherapy · Anti-angiogenesis agent

Marketed (1)

• Primary Medical Treatment Pathway · Moorfields Eye Hospital NHS Foundation Trust · anti-VEGF agent · Ophthalmology
  This drug works by inhibiting the action of vascular endothelial growth factor (VEGF) to reduce angiogenesis.

Phase 3 pipeline (5)

• VB-111 + bevacizumab · Vascular Biogenics Ltd. operating as VBL Therapeutics · Antiangiogenic agent · Oncology
  VB-111 is a targeted therapy that works by inhibiting the expression of vascular endothelial growth factor (VEGF) mRNA, while bevacizumab is a monoclonal antibody that directly binds to VEGF.
• conbercept, Fixed · Chengdu Kanghong Biotech Co., Ltd. · VEGF decoy receptor · Ophthalmology
  Conbercept is a recombinant human VEGF decoy receptor that inhibits angiogenesis.
• OCS-01 · Oculis · anti-VEGF inhibitor · Ophthalmology
  OCS-01 is an anti-vascular endothelial growth factor (VEGF) inhibitor.
• mFOLFOX6-bevacizumab · GERCOR - Multidisciplinary Oncology Cooperative Group · chemotherapy regimen · Oncology
  mFOLFOX6-bevacizumab is a chemotherapy regimen that combines oxaliplatin, 5-fluorouracil, and leucovorin with bevacizumab, an anti-angiogenic monoclonal antibody.
• VB-111 + Paclitaxel · Vascular Biogenics Ltd. operating as VBL Therapeutics · VEGF aptamer and microtubule inhibitor · Oncology
  VB-111 is a targeted anti-vascular endothelial growth factor (VEGF) aptamer that inhibits tumor growth by blocking VEGF, while Paclitaxel is a microtubule inhibitor that disrupts cell division.

Phase 2 pipeline (5)

• Avacincaptad Pegol intravitreal solution · ONL Therapeutics · anti-VEGF agent · Ophthalmology
  Avacincaptad pegol is an anti-vascular endothelial growth factor (VEGF) agent.
• Anti-VEGF injections · Bayer · Anti-angiogenic agent · Oncology
  Anti-VEGF injections work by binding to and inhibiting vascular endothelial growth factor (VEGF), a protein that promotes angiogenesis.
• Avastin in combination with Roferon-A · Central European Society for Anticancer Drug Research · Antiangiogenic agent and Immunomodulator · Oncology
  Avastin (bevacizumab) inhibits angiogenesis by binding to vascular endothelial growth factor (VEGF), while Roferon-A (interferon alfa-2a) modulates the immune response and has antiproliferative effects.
• Anti-VEGF treatment · Vastra Gotaland Region · Anti-angiogenic agent · Oncology
  Anti-VEGF treatment works by inhibiting the vascular endothelial growth factor (VEGF) pathway, which is involved in angiogenesis and tumor growth.
• Avastin, Alimta · The Cooper Health System · monoclonal antibody · Oncology
  Avastin (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor growth.

Phase 1 pipeline (2)

• ADH -1 and carboplatin · Adherex Technologies, Inc. · Angiogenesis inhibitor and platinum-based chemotherapy · Oncology
  Antiangiogenic and platinum-based chemotherapy
• Anti-angiogenesis · Amgen · Anti-angiogenesis agent · Oncology
  Inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF)